#Investors and #Media
Please read our cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures in our 2025 Annual Report. CER% represents constant exchange rates. AER% represents actual exchange rates. $GSK
For investors: bit.ly/4d1ASoz
Published today, our latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders.
Take a look at the highlights ⤵️
🔗 Investors and media can read more: gsk.to/4rTabHu
Today we’re at #SLEuro discussing the importance of early intervention and its role in reducing the risk of organ damage progression for patients with lupus and lupus nephritis.
#News for #investors and #media: Today we announced the completion of our acquisition of RAPT Therapeutics, adding to our growing Respiratory, Immunology & Inflammation (RI&I) pipeline.
Find out more: gsk.to/4bjpC5H
City scape shot of Philadelphia
We’re on the ground at #AAAAI26, sharing our latest #RespiratoryHealth research this week. Stop by Booth 1137 to learn more 🫁
#News for #investors and #media: Today we are announcing our potential treatment for chronic hepatitis B has been accepted for regulatory review in Japan.
Learn more: gsk.to/3MKpqTS
News for #Investors and #Media:
Today at #CROI2026, our specialist HIV company ViiV Healthcare, presented new insights on our investigational long-acting therapies.
🔗 Find out more on our website: gsk.to/4sfUv0S
#News for #investors and #media: We’ve announced an agreement to acquire 35Pharma.
Find out more: gsk.to/3ZS9thp
News for #Investors and #Media:
New data published in the New England Journal of Medicine compare efficacy of different forms of HIV treatment for people with adherence challenges.
🔗 Find out more on our website: gsk.to/40fqNNh
#News for #Investors and #Media: Today we are presenting new data about one of our vaccines.
Learn more: gsk.to/4bZNQ66
#News for #investors and #media: The European Commission has approved our new therapy to treat two respiratory diseases.
Learn more here: gsk.to/4tzOptr
#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been accepted for review by the China National Medical Products Administration.
Learn more: gsk.to/4qnf6Pd
Tuberculosis is a serious and contagious lung disease, with 10 million people worldwide falling ill with it each year. New treatment options are needed, and research collaborations like our work with @dundee.ac.uk are essential to keep innovation at the forefront in the fight against TB.
#News for #investors and #media: We have announced that the European Commission has approved a new therapy for use in adults with chronic obstructive pulmonary disease (COPD).
Learn more here: gsk.to/3O0TpXN
#Investors and #Media Please read our cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. $GSK For investors: www.gsk.com/en-gb/invest...
Today we announce our strong 2025 performance, driven mainly by Specialty Medicines, and reaffirm our long-term outlooks.
Hear more from our CEO Luke Miels ⤵️
More information for media and investors: gsk.to/4r7A5qv $GSK #earnings
Today on #WorldNTDDay, we’re reinforcing our commitment to helping eliminate neglected tropical diseases (NTDs) through our new three-year project with the END Fund. Their expertise means they are ideally placed to deliver this project, helping towards eliminating NTDs 🙌#UniteActEliminate #EndNTDs
#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded indication by the European Commission (EC).
Learn more: gsk.to/49XpQhi
#News for #investors and #media: We have announced that China’s health authority has approved one of our therapies for use in adults with asthma.
Learn more here: gsk.to/4pQb3e1
We’ve announced an agreement to acquire RAPT Therapeutics.
Find out more: gsk.to/4qwhWT9
GSK's Tony Wood sitting on a panel at the JP Morgan Healthcare Conference.
Five panellists, including GSK's Chris Sheldon, are seated on a stage at the JP Morgan Healthcare Conference, facing an audience whose backs are visible.
A classic green and red San Francisco cable car is stopped on tracks on a city street. Tall trees line the street with buildings are visible in the background.
GSK's Kaivan Khavandi sitting on a panel at the JP Morgan Healthcare Conference.
That's a wrap on #JPM2026!
We're leaving inspired and confident in our R&D momentum and the future impact of our pipeline. Our approach, built on cutting-edge innovation and industry-leading partnerships, is driving us to get ahead of disease together.
Check out our highlights ⤵️
#AheadTogether
Innovation starts when we stop to listen.
Patients' experiences fuel our innovation, inspiring us to help people live happier, fuller lives.
🎥 Hear from the people who drive our purpose.
#AheadTogether #JPM2026 #JPM26
Text reads: "At GSK, we unite science, technology and talent to get ahead of disease together." Image depicts four scientists in white lab coats, two men and two women, smiling and engaged in conversation around a whiteboard in a modern laboratory setting.
Text reads: "Our R&D approach is driving pipeline momentum and future growth." Below this, it details "15 scale opportunities to launch by 2031" and "5 major pivotal data readouts in 2026."
Text reads: "Our partnerships focus on industry-leading capabilities, cutting-edge innovation, and advanced tech" Image depicts close-up of automated laboratory equipment, showing multiple robotic pipettes precisely dispensing liquid into a tray of vials.
Text reads: "To developed medicines and vaccines that prevent and treat the most challenging diseases." Image depicts a smiling young child being held by a female adult. The child is looking directly at the camera with a joyful expression, while the female looks towards the child.
Heading to #JPM2026?
We’re joining our investor and industry partners and sharing how our R&D momentum, pipeline progress and strategic investments are driving innovation for patients.
See you there!
🔗 gsk.to/4buPbkT
#News for #Investors and #Media: The European Commission (EC) has approved a new prefilled syringe presentation of one of our vaccines.
👉 Learn more: gsk.to/3LvBgAu
#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programmes for chronic hepatitis B (CHB).
This marks an important step towards addressing the global burden of CHB.
Learn more: gsk.to/49HDLZM
#News for #investors and #media:
A new therapy for two respiratory diseases has received approval from Japan’s health authority.
Learn more here: gsk.to/3Lm8ZfI
#News for #investors and #media:
We have announced that China’s health authority has approved one of our therapies for use in adults with a respiratory disease.
Learn more here: gsk.to/4jqC3PO
Happy New Year from all of us! 🎉
As we step into 2026, our commitments remain strong. We're excited to continue on our journey to get ahead of disease together.
What are you looking forward to achieving in 2026?
Season’s greetings from us at GSK to you! 🎄
May your day be filled with peace, happiness and special moments shared with those closest to you ✨
From our network to yours, we’re wishing you a happy holiday season from across the globe!
Dive into the festive spirit and hear directly from our manufacturing teams who ensure our vital medicines and vaccines reach patients, even during this special time of year.👇
